Stock listing
OTC:OTLC Oncotelic Therapeutics Inc Stock
Follow Oncotelic Therapeutics Inc into a list and get an email when it puts out news.
Share price · OTC:OTLC
$0.012 USD -0.001 (-9.6%)
Close on Nov 20, 2026
- Day range
- $0.012 – $0.012 USDNov 20, 2026
- Volume
- 26,750 sharesNov 20, 2026
- Market cap
- $5.58M USDAt the close on Nov 20, 2026 · price × 457.5M shares outstanding
- 52-week range
- $0.010 – $0.100 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $8,459 USDMedian day 285,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:OTLC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.012 | -0.001 | -9.6% | $0.012 | $0.012 | $0.012 | 26,750 | |
| $0.014 | +0.001 | +8.0% | $0.013 | $0.014 | $0.013 | 40,000 | |
| $0.013 | -0.001 | -6.7% | $0.012 | $0.013 | $0.012 | 65,500 | |
| $0.013 | +0.000 | +3.1% | $0.012 | $0.013 | $0.012 | 74,700 | |
| $0.013 | 0.000 | -2.3% | $0.012 | $0.013 | $0.012 | 320,000 | |
| $0.013 | +0.003 | +33.0% | $0.014 | $0.014 | $0.012 | 274,225 | |
| $0.010 | 0.000 | 0.0% | $0.020 | $0.020 | $0.010 | 635,300 | |
| $0.010 | -0.010 | -50.0% | $0.020 | $0.020 | $0.010 | 285,200 | |
| $0.020 | +0.010 | +100.0% | $0.010 | $0.020 | $0.010 | 836,600 | |
| $0.010 | 0.000 | 0.0% | $0.010 | $0.010 | $0.010 | 92,300 | |
| $0.010 | -0.010 | -50.0% | $0.020 | $0.020 | $0.010 | 730,900 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 684,200 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 229,300 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 728,800 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.030 | $0.020 | 289,800 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 390,600 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 1,363,000 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 699,600 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 342,000 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 254,100 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 57,100 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 238,300 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 227,000 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 204,600 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 385,800 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 504,500 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 850,900 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 438,400 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 657,100 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 480,100 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.030 | $0.020 | 183,800 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 327,200 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.030 | $0.020 | 551,400 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 107,700 | |
| $0.020 | 0.000 | 0.0% | $0.030 | $0.030 | $0.020 | 274,700 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 1,380,100 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 271,700 | |
| $0.020 | -0.010 | -33.3% | $0.020 | $0.030 | $0.020 | 428,300 | |
| $0.030 | 0.000 | 0.0% | $0.020 | $0.030 | $0.020 | 328,200 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 299,900 | |
| $0.030 | +0.010 | +50.0% | $0.030 | $0.030 | $0.020 | 629,000 | |
| $0.020 | 0.000 | 0.0% | $0.030 | $0.030 | $0.020 | 365,700 | |
| $0.020 | -0.010 | -33.3% | $0.030 | $0.030 | $0.020 | 827,400 | |
| $0.030 | +0.010 | +50.0% | $0.020 | $0.030 | $0.020 | 843,900 | |
| $0.020 | -0.010 | -33.3% | $0.030 | $0.030 | $0.020 | 163,300 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 221,800 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 403,600 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 195,400 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 675,500 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 31,400 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 268,000 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 90,000 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 326,000 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.040 | $0.030 | 126,700 | |
| $0.030 | -0.010 | -25.0% | $0.030 | $0.030 | $0.030 | 10,500 | |
| $0.040 | +0.010 | +33.3% | $0.030 | $0.040 | $0.030 | 233,300 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 156,300 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 87,100 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 75,800 | |
| $0.030 | 0.000 | 0.0% | $0.030 | $0.030 | $0.030 | 248,400 | |
| $0.030 | 0.000 | 0.0% | $0.040 | $0.040 | $0.030 | 1,180,700 | |
| $0.030 | -0.010 | -25.0% | $0.040 | $0.040 | $0.030 | 163,400 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.030 | 433,100 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 138,900 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 99,600 |
Splits
2 splits since 2011 · OTC:OTLC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- OTC:OTLC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 26, 2026
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
Latest deck · Oct 26, 2026
22nd Drug Discovery Strategic Summit (October 2026)
Conference · 16 slides
Latest news
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
Oct 26, 2026
Closed $0.02 (0.0%) on Oct 26, 2026
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery
Oct 20, 2026
Closed $0.02 (0.0%) on Oct 20, 2026
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Oct 5, 2026
Closed $0.02 (0.0%) on Oct 5, 2026
Oncotelic Therapeutics Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 3 in all · newest Oct 26, 2026 · oldest 2026
- Decks
- 32 decks · latest Oct 26, 2026
Valuation
P/E 0.0× against a median of 2.6×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.52M USD
- P/E
- 0.0×
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.07
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Oncotelic Therapeutics Inc · OTC:OTLC | US$5.58M | US$5.52M | 0.0× | n/a | n/a | 0.0× | n/a | 0.0× | 0.07 |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Marvel Biosciences Corp · TSXV:MRVL | US$5.91M | US$6.04M | n/a | n/a | n/a | n/a | n/a | n/a | 0.91 |
| Exicure, Inc. · NASDAQ:XCUR | US$5.89M | US$4.67M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.49 |
| Tempest Therapeutics, Inc. · NASDAQ:TPST | US$5.74M | US$4.84M | n/a | n/a | n/a | n/a | n/a | n/a | 1.09 |
| Theriva Biologics, Inc. · AMEX:TOVX | US$5.51M | US$461,120 | n/a | n/a | n/a | 0.5× | n/a | 0.3× | 2.65 |
| Hemostemix Inc · TSXV:HEM | US$5.35M | US$7.70M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Curative Biotechnology Inc · OTC:CUBT | US$5.34M | US$6.55M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| Abpro Holdings, Inc. · OTC:ABPO | US$5.31M | US$1.07M | 2.6× | n/a | n/a | n/a | n/a | n/a | -0.79 |
| CNS Pharmaceuticals, Inc. · NASDAQ:CNSP | US$5.25M | −US$11.96M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.74 |
| Median of the others | US$5.62M | US$4.75M | 2.6× | 68.2× | 1.5× | 0.0× | 0.83 |
Team and board
| Officer | Role |
|---|---|
| Vuong Trieu | CEO/Chairman of Oncotelic Inc. |
| Amit Shah | CFO |
| Anthony E. Maida | Chief Clinical Officer-Translational Medicine |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 24, 2026 | −25.0% |
| Q1 2026 | Apr 20, 2026 | 0.0% |
| Q3 2025 | Nov 28, 2025 | 0.0% |
| Q2 2025 | Aug 29, 2025 | 0.0% |
| Q1 2025 | May 12, 2025 · After close | 0.0% |
| Q4 2024 | Feb 26, 2025 | 0.0% |
| Q3 2024 | Nov 12, 2024 · Before open | 0.0% |
| Q2 2024 | Aug 14, 2024 · After close | 0.0% |
| Q1 2024 | Apr 12, 2024 · After close | 0.0% |
| Q3 2023 | Nov 14, 2023 · Before open | −25.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 18, 2023 · After close | 0.0% |
| Q1 2023 | Apr 14, 2023 · After close | 0.0% |
| Q4 2022 | Mar 1, 2023 | 0.0% |
| Q3 2022 | Nov 18, 2022 · After close | 0.0% |
| Q2 2022 | Aug 22, 2022 · Before open | −11.1% |
| Q1 2022 | Apr 15, 2022 · After close | 0.0% |
| Q4 2021 | Mar 2, 2022 | +4.2% |
| Quarter to Sep 30, 2021 | Nov 22, 2021 · After close | 0.0% |
| Quarter to Jun 30, 2021 | Aug 20, 2021 · After close | 0.0% |
| Quarter to Mar 31, 2021 | May 24, 2021 · After close | −3.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 22nd Drug Discovery Strategic Summit (October 2026) | Conference | 16 slides | Oct 26, 2026 |
| Drug Discovery-2026 | Conference | 13 slides | Oct 13, 2026 |
| Drug Discovery 2026 | Conference | 13 slides | Oct 13, 2026 |
| Investor Presentation (July 2026) | Investor deck | 5 slides | Jul 14, 2026 |
| Investor Presentation (October 2025) | Investor deck | 37 slides | Oct 22, 2025 |
| 5th Symposium on World Cancer Research (SWCR 2025) | Conference | 36 slides | Mar 24, 2025 |
| Technical Presentation (July 2022) | Technical | 11 slides | Jul 15, 2022 |
| Investor Presentation (June 2022) | Investor deck | 18 slides | June 2022 |
| MedInvest March 2022 | Conference | 22 slides | Apr 1, 2022 |
| Investor Presentation (February 2022) | Investor deck | 13 slides | Feb 9, 2022 |
All 32 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.0K | 1.74M | ||||||||
| Research and development | 4.36K | 61.1K | 756.9K | 3.66M | 4.30M | 1.37M | 649.8K | 10.5M | 8.76M | |
| Operating income | -3.19M | -3.58M | -6.65M | -9.72M | -9.13M | -7.58M | -4.31M | -712.7K | -13.8M | -13.8M |
| Depreciation and amortization | 10.1K | 37.4K | 9.24K | 2.00K | 9.00K | 19.0K | ||||
| EBITDA | -9.12M | -7.55M | -4.30M | -710.7K | -13.8M | -13.7M | ||||
| Interest expense | 1.04M | 2.97M | 2.00M | 2.00M | 749.5K | |||||
| Income before tax | 360.6M | -4.78M | ||||||||
| Income tax | 111.5M | |||||||||
| Net income | 249.3M | -4.52M | -7.90M | 5.09M | -9.39M | -9.50M | -6.64M | -712.7K | -13.8M | -13.7M |
| Earnings per share, basic | 0.59 | 0.01 | -0.02 | 0.01 | -0.03 | -0.11 | -0.11 | -0.12 | -0.52 | -0.51 |
| Earnings per share, diluted | 0.59 | -0.01 | -0.02 | 0.01 | -0.03 | -0.11 | -0.11 | -0.12 | -0.52 | -0.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 88.9K | 86.1K | 170.4K | 241.5K | 568.8K | 474.0K | 82.0K | 2.50K | 1.11M | 3.54M |
| Short-term investments | 8.51M | |||||||||
| Receivables | 51.3K | 19.0K | 19.0K | 19.7K | 19.7K | 19.7K | 149.7K | |||
| Current assets | 1.20M | 134.2K | 271.7K | 303.2K | 627.3K | 615.6K | 273.0K | 2.50K | 1.14M | 14.1M |
| Property, plant and equipment | 47.6K | 2.00K | 11.0K | |||||||
| Goodwill | 2.79M | 2.79M | 5.99M | 12.1M | 21.1M | 21.1M | 21.1M | |||
| Total assets | 393.1M | 26.7M | 30.0M | 36.1M | 23.6M | 23.7M | 23.7M | 2.75M | 1.17M | 14.1M |
| Accounts payable | 332.4K | 1.93M | 1.94M | 1.79M | 915.0K | 788.0K | 310.0K | |||
| Current liabilities | 18.1M | 19.2M | 16.5M | 16.9M | 15.5M | 11.2M | 6.78M | 283.0K | 1.65M | 1.61M |
| Total liabilities | 131.4M | 19.2M | 18.4M | 16.9M | ||||||
| Shareholders' equity | 262.8M | 8.25M | 12.1M | 19.4M | 7.96M | 11.8M | 16.9M | 2.46M | -483.6K | 12.5M |
| Shares outstanding | 442.6M | 407.3M | 399.2M | 391.8M | 375.3M | 90.6M | 84.1M | 6.84M | 26.5M | 26.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.38M | -740.3K | -1.32M | -1.45M | -4.43M | -2.81M | -2.28M | -241.0K | -10.9M | -15.2M |
| Cash from investing | 189.3K | 8.51M | -8.51M | |||||||
| Cash from financing | 1.39M | 656.0K | 1.25M | 1.13M | 4.53M | 3.22M | 2.17M | 240.0K | ||
| Change in cash | 2.73K | -84.3K | -71.0K | -327.3K | 94.8K | 412.1K | 79.5K | -980 | -2.42M | -23.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| D | Jul 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jul 14, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 29, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Apr 16, 2026 | Current report | SEC |
| 10-K · Annual report | Apr 15, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 2, 2026 | Material contract | SEC |
| NT 10-K · Late filing notice | Mar 31, 2026 | Explanation request | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| 8-K · Current report | Mar 27, 2026 | Current report | SEC |
| 8-K · Current report | Jan 29, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 26, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 7, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 6, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 6, 2026 | Material contract | SEC |
| 8-K · Current report | Dec 30, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Dec 29, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Dec 22, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 22, 2025 | Offer document | SEC |
| D | Dec 11, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 9, 2025 | Material contract | SEC |
| S-1 · Registration statement | Nov 21, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 17, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2025 | Explanation request | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 6, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | Apr 29, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 22, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 15, 2025 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 19, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2024 | Current report | SEC |
| 424B3 · Prospectus | Apr 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 23, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 18, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 12, 2024 | Offer document | SEC |
| 10-K · Annual report | Apr 12, 2024 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2024 | Explanation request | SEC |
| 8-K · Current report | Feb 2, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2023 | Material contract | SEC |
| 8-K · Current report | Aug 23, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 18, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2023 | Explanation request | SEC |
| D | Jul 13, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 13, 2023 | Material contract | SEC |
| 4 · Change in ownership | Jun 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 19, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 19, 2023 | Current report | SEC |
| NT 10-Q · Late filing notice | May 15, 2023 | Explanation request | SEC |
| 424B3 · Prospectus | May 2, 2023 | Offer document | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 26, 2023 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 19, 2023 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 19, 2023 | Annual report | SEC |
| POS AM · Amendment to an effective registration | Apr 14, 2023 | Offer document | SEC |
| 10-K · Annual report | Apr 14, 2023 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2023 | Explanation request | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 8-K · Current report | Mar 2, 2023 | Management or board change | SEC |
| 8-K · Current report | Jan 3, 2023 | Current report | SEC |
| 8-K · Current report | Dec 20, 2022 | Current report | SEC |
| 4 · Change in ownership | Dec 7, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 18, 2022 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2022 | Explanation request | SEC |
| 4 · Change in ownership | Sep 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 22, 2022 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2022 | Explanation request | SEC |
| 8-K · Current report | Jul 15, 2022 | Current report | SEC |
| 8-K · Current report | Jun 27, 2022 | Material contract | SEC |
| 8-K · Current report | Jun 22, 2022 | Current report | SEC |
| 8-K · Current report | Jun 3, 2022 | Material contract | SEC |
| 10-Q · Quarterly report | May 23, 2022 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 16, 2022 | Explanation request | SEC |
| 424B3 · Prospectus | May 11, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 9, 2022 | Other filings | SEC |
| 8-K · Current report | May 6, 2022 | Management or board change | SEC |
| POS AM · Amendment to an effective registration | Apr 26, 2022 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2022 | Annual report | SEC |
| 8-K · Current report | Apr 13, 2022 | Current report | SEC |
| 8-K · Current report | Apr 6, 2022 | Material contract | SEC |
| 8-K · Current report | Apr 4, 2022 | Material contract | SEC |
| 8-K · Current report | Apr 1, 2022 | Current report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2022 | Explanation request | SEC |
| 8-K · Current report | Feb 17, 2022 | Current report | SEC |
| 8-K · Current report | Feb 15, 2022 | Material contract | SEC |
| 8-K · Current report | Feb 9, 2022 | Current report | SEC |
| 8-K · Current report | Feb 2, 2022 | Material contract | SEC |
| 8-K · Current report | Jan 28, 2022 | Current report | SEC |
| 8-K · Current report | Dec 23, 2021 | Current report | SEC |
| 8-K · Current report | Dec 15, 2021 | Material contract | SEC |
| 8-K · Current report | Dec 1, 2021 | Material contract | SEC |
| 8-K · Current report | Nov 24, 2021 | Current report | SEC |
| 8-K · Current report | Nov 23, 2021 | Results | SEC |
| 10-Q · Quarterly report | Nov 22, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2021 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 15, 2021 | Explanation request | SEC |
| 8-K · Current report | Oct 28, 2021 | Material contract | SEC |
| 8-K · Current report | Oct 4, 2021 | Material contract | SEC |
| 8-K · Current report | Sep 27, 2021 | Material contract | SEC |
| 424B3 · Prospectus | Sep 24, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 10, 2021 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2021 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2021 | Current report | SEC |
| S-3/A · Registration statement, amended | Sep 7, 2021 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2021 | Material contract | SEC |
| 8-K · Current report | Aug 26, 2021 | Current report | SEC |
| S-3 · Registration statement | Aug 20, 2021 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 20, 2021 | Quarterly report | SEC |
| 8-K · Current report | Aug 17, 2021 | Current report | SEC |
| NT 10-Q · Late filing notice | Aug 16, 2021 | Explanation request | SEC |
| 8-K · Current report | Aug 5, 2021 | Material contract | SEC |
| 8-K · Current report | Jul 19, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2021 | Material contract | SEC |
| 8-K · Current report | Jun 15, 2021 | Current report | SEC |
| 424B3 · Prospectus | Jun 3, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2021 | Other filings | SEC |
| 8-K · Current report | Jun 1, 2021 | Material contract | SEC |
| CORRESP · Letter to the SEC | May 28, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 27, 2021 | Other filings | SEC |
| S-1 · Registration statement | May 24, 2021 | Offer document | SEC |
| 10-Q · Quarterly report | May 24, 2021 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 17, 2021 | Explanation request | SEC |
| 8-K · Current report | May 7, 2021 | Material contract | SEC |
| 8-K · Current report | Apr 21, 2021 | Current report | SEC |
| S-8 · Registration statement for employee plans | Apr 16, 2021 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2021 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2021 | Explanation request | SEC |
| 8-K · Current report | Mar 30, 2021 | Current report | SEC |
| 8-K · Current report | Mar 26, 2021 | Material contract | SEC |
| 8-K · Current report | Mar 2, 2021 | Current report | SEC |
| 8-K · Current report | Feb 18, 2021 | Current report | SEC |
| 8-K · Current report | Feb 2, 2021 | Current report | SEC |
| 8-K · Current report | Feb 2, 2021 | Current report | SEC |
| 8-K · Current report | Feb 2, 2021 | Current report | SEC |
| 8-K · Current report | Feb 1, 2021 | Current report | SEC |
| 8-K · Current report | Jan 15, 2021 | Current report | SEC |
| 8-K · Current report | Dec 15, 2020 | Current report | SEC |
| 8-K · Current report | Dec 3, 2020 | Current report | SEC |
| 4 · Change in ownership | Nov 24, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Nov 23, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Nov 23, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 16, 2020 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2020 | Current report | SEC |
| 8-K · Current report | Oct 21, 2020 | Current report | SEC |
| 8-K · Current report | Sep 30, 2020 | Current report | SEC |
| 8-K · Current report | Sep 28, 2020 | Current report | SEC |
| 8-K · Current report | Sep 21, 2020 | Current report | SEC |
| 8-K · Current report | Aug 24, 2020 | Current report | SEC |
| 8-K · Current report | Aug 19, 2020 | Current report | SEC |
| 8-K · Current report | Aug 13, 2020 | Meeting outcome | SEC |
This page holds 200 of 1,008 filings. Open Filings
Cap table
Built by 6ix from Oncotelic Therapeutics Inc’s releases · as of Nov 13, 2026
- Common shares
- 457,512,796
- Fully diluted
- 457,512,796
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 457,512,796 | Nov 13, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 457,512,796 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anthony E Maida III Other companies: Range Impact Inc (Director · Mar 16, 2012 – May 8, 2019 · Past); Spectrum Pharmaceuticals Inc (Director · Feb 20, 2007 – May 29, 2019 · Past) | DIRECTOR AND CMO - TRANS. MED., Director · Since at least May 11, 2020 |
| Bobby W Phd Sandage Other companies: Fortress Biotech, Inc. (President, Director · Sep 13, 2011 – Apr 5, 2013 · Past); Indevus Pharmaceuticals Inc (Executive Vice President · Jan 25, 2006 – Feb 23, 2009 · Past) | Director · Oct 25, 2016 – Jun 20, 2018 · Past |
| Gerald PhD McMahon Other companies: Harpoon Therapeutics Inc (President and CEO, Director · Feb 7, 2019 – Jan 28, 2021 · Past); Celldex Therapeutics, Inc. (Director · Dec 14, 2016 – Dec 3, 2018 · Past) | Director · Sep 2, 2011 – Jun 1, 2016 · Past |
| Amit Shah | CFO · Since at least Nov 5, 2026 |
| Anthony E. Maida | Chief Clinical Officer-Translational Medicine · Since at least Nov 5, 2026 |
| Chulho Park | CHIEF TECHNOLOGY OFFICER · Apr 22, 2019 – Nov 19, 2020 · Past |
| Donald Rogers Reynolds | Director · Oct 25, 2016 – Jun 20, 2018 · Past |
| Matthew M Loar | Chief Financial Officer · Jul 20, 2015 – Jun 20, 2018 · Past |
| Pamela Ha | Controller · Jun 4, 2015 – Jun 4, 2015 · Past |
| Per Olof Soderberg | Director · Mar 15, 2006 – Dec 15, 2006 · Past |
All 15 people
| Person | Seat |
|---|---|
| Saran Saund | CBO · Since at least Mar 31, 2021 |
| Seymour Howard Fein | CRO/CMO · Since at least Jul 10, 2026 |
| Steven W. King | Inc. · Until Oct 30, 2026 · Past |
| Vuong Trieu | CEO/Chairman of Oncotelic Inc. · Since at least Jul 8, 2025 |
| William D Schwieterman | President and CEO, Director · Mar 21, 2016 – Jun 20, 2018 · Past |
Log in to ask 6ix AI your own questions about Oncotelic Therapeutics Inc.